PreMD Inc. To Hold Year-End Update Conference Call

TORONTO, March 6 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. today announced it will hold a conference call and webcast on Wednesday, March 15, 2006 at 10 a.m. (ET) to preview financial results for the fourth quarter and fiscal year ended December 31, 2005 and to provide an operating update and outlook for fiscal 2006.

The event will be hosted by Dr. Brent Norton, President and CEO; Ron Hosking, Vice President and CFO; and Sarah Borg-Olivier, Director, Communications. To listen to the conference call, please dial (416) 644-3425 (Toronto) or (800) 814-3911 (North America). The event will be webcast live at www.premdinc.com or www.newswire.ca and subsequently archived for three months.

A replay of the call will be available until March 24, 2006 by dialing (416) 640-1917 (Toronto) or (877) 289-8525 (North America) and entering access code 21180267 followed by the number sign.

About PreMD Inc.

PreMD Inc. is a world leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products, which are branded as PREVU(x) Skin Sterol Test, are marketed and distributed worldwide by McNeil Consumer Healthcare, Canada. The company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, and its research and product development facility is at McMaster University in Hamilton, Ontario.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions.

In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

CONTACT: Sarah Borg-Olivier, Director, Communications, T: (416) 222-3449,sbolivier@premdinc.com